Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lou-Gehrigs Disease Clear all
Completed Phase 2Phase 3 Interventional

Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis

NCT00706147
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Arimoclomol, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Miami, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of High Dose CoQ10 in ALS

NCT00243932
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease
Interventions
coenzyme Q10, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
19
States / cities
Little Rock, Arkansas • San Francisco, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional

Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00072709
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
TCH346
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Not applicable Interventional Results available

Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation

NCT00116558
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Early NIPPV, Standard NIPPV
Device
Lead sponsor
Edward Kasaraskis
Other
Eligibility
18 Years to 80 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
12
States / cities
Denver, Colorado • Miami, Florida • Lexington, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Jun 10, 2026, 2:10 PM EDT
Withdrawn Phase 2 Interventional

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

NCT00561366
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo, Arimoclomol
Drug
Lead sponsor
CytRx
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Pacific Palisades, California • San Francisco, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Jun 10, 2026, 2:10 PM EDT
Recruiting No phase listed Observational

The National Amyotrophic Lateral Sclerosis Registry

NCT01772602
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2040
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS)

NCT00809224
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

NCT05136885
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
SLS-005, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen G DNL343

NCT05842941
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
DNL343, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)

NCT00677768
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Primary Lateral Sclerosis, Nervous System Diseases, Hereditary Spastic Paraparesis
Interventions
No intervention
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 80 Years
Enrollment
475 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
29
States / cities
Phoenix, Arizona • Orange, California • Jacksonville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

NCT03520517
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease, Lou-Gehrigs Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
BHV-0223
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Lincoln, Nebraska • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis

NCT02039401
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
VM202
Biological
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
21 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Multiple Doses of AT-1501-A201 in Adults With ALS

NCT04322149
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AT-1501
Drug
Lead sponsor
Anelixis Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

NCT01257581
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
creatine, tamoxifen
Drug
Lead sponsor
Nazem Atassi
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Kansas City, Kansas • Boston, Massachusetts • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Dexpramipexole in ALS

NCT01281189
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
43
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT00790582
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
lithium carbonate
Drug
Lead sponsor
Forbes Norris MDA/ALS Research Center
Other
Eligibility
21 Years to 80 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen A Zilucoplan

NCT04436497
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Zilucoplan, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Jun 10, 2026, 2:10 PM EDT
Active, not recruiting Phase 2 Interventional

T-regulatory Cells in ALS

NCT04055623
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections, Monthly placebo infusions + 3 times per week placebo injections
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Jun 10, 2026, 2:10 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

HEALEY ALS Platform Trial - Regimen I NUZ-001

NCT07410806
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
NUZ-001, Matching placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen C CNM-Au8

NCT04414345
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CNM-Au8, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Jun 10, 2026, 2:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetics of Familial and Sporadic ALS

NCT00821132
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Familial Amyotrophic Lateral Sclerosis, ALS With Frontotemporal Dementia (ALS/FTD), Lou Gehrig's Disease, Motor Neuron Disease (MND), Primary Lateral Sclerosis (PLS), Sporadic ALS (SALS)
Interventions
Genetic study of ALS families
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
13,521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jun 10, 2026, 2:10 PM EDT
No Longer Available No phase listed Expanded access

Intermediate-Sized Expanded Access Study

NCT05597436
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Trehalose
Drug
Lead sponsor
Seelos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
21
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)

NCT00931944
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
KNS-760704
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
21 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Jun 10, 2026, 2:10 PM EDT
Suspended Phase 1 Interventional

Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis

NCT01082653
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
autologous bone marrow-derived stem cells
Biological
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jun 10, 2026, 2:10 PM EDT